Shift the standard of care for cancer from reactive diagnosis to proactive prevention.
Clairity’s mission is grounded in the belief that everyone deserves to understand their health risks, regardless of race, ethnicity or gender. Within the domain of radiomics, advancements in AI unlock new insights from the data embedded in the image, accurately identifying those individuals who have the highest risk of developing cancer. These insights, in turn, enable clinicians to personalize a plan of care for each patient, and evolve that plan over time, monitoring lifestyle choices, changes in health, information regarding family history, and more.
Founded in 2020 and headquartered in Boston, Massachusetts, Clairity, Inc. is transforming healthcare risk assessment through the power of artificial intelligence and deep learning. Founded by Dr. Connie Lehman, backed by Santé Ventures and ACE Global Equity, Clairity’s technology can uncover subtle patterns in routine images that are invisible to the human eye, enhancing risk prediction to empower clinicians and their patients with actionable, personalized insights. Clairity’s mission is to shift the standard of care from late-stage treatment to proactive prevention.
CLAIRITY BREAST, authorized under the name Allix5, is a mammography-based AI risk prediction platform that analyzes imaging data at the pixel level to identify individuals at elevated risk of future breast cancer. The AI model behind CLAIRITY BREAST was trained on millions of images and validated across more than 77,000 mammograms from five geographically distinct screening centers – including hospital-based and free-standing facilities – that collectively serve a diverse patient population, with validation anchored in five-year outcome data.
Clairity’s first-in-class platform was designed to complement existing clinician workflows, making it uniquely positioned to address, at scale, the widespread shortfalls in breast cancer risk assessment and cancer prevention.
The Clairity team brings with it extensive clinical and health technology experience, along with decades focused on improving the lives of others.
Chief Executive Officer
Chief Technology Officer
Co-Founder, Board of Directors Managing Director, Santé Ventures
Board of Directors Managing Director, Santé Ventures
Founder, Protea Institute M.S. MIT Sloan School of Management
Clairity’s founding data partners were chosen for their thought leadership, clinical expertise, diversity of patients, focus on data excellence, and international scale.
